## Organic & Biomolecular Chemistry

Cite this: Org. Biomol. Chem., 2012, 10, 724

## Multicomponent approaches to 8-carboxylnaphthyl-functionalized pyrazolo[3,4-*b*]pyridine derivatives†

Yan Hao, Xiao-Ping Xu,\* Tao Chen, Li-Li Zhao and Shun-Jun Ji\*

Received 23rd September 2011, Accepted 15th November 2011 DOI: 10.1039/c1ob06624b

A simple and novel protocol for the efficient synthesis of a series of 8-carboxylnaphthyl functionalized pyrazolo[3,4b]pyridine derivatives was developed through a one-pot, three-component reaction involving acenaphthylene-1,2dione and 1*H*-pyrazol-5-amine in acetic acid medium. The reaction represents the first facile conversion of acenaphthenequinone to naphthoic acid via C-C bond cleavage without need for multi-step transformation.

The pyrazolo[3,4-b]pyridine ring system<sup>1</sup> is present in a number of pharmaceutically important compounds targeted, for instance, to inhibit (or potentially inhibit) glycogen synthase kinase-3 (GSK-3),<sup>2</sup> xanthine oxidases,<sup>3</sup> cholesterol formation,<sup>4</sup> A1 adenosine receptors,<sup>5</sup> phosphodiesterase 4 (PDE4) in immune and inflammatory cells,6 p38 as anti-inflammatory drugs,7 and to treat Alzheimer's disease, gastrointestinal diseases, anorexia nervosa, drug and alcohol withdrawal symptoms, drug addiction and infertility.8 Naphthoic acid is also a key motif which often occurs in several biologically active natural products and pharmaceutical compounds,<sup>9-13</sup> and its derivatives have been reported to play a vital role in the development of new drugs against several human ailments and infectious diseases.<sup>14-17</sup> Functionalization of naphthoic acid at the 8-position with macrocycles such as porphyrin exhibited interesting properties. Chang et al. disclosed that Co(II) 1-naphthylporphyrin-substituted with a carboxyl group at the 8-naphthyl position displayed significant enhancement in O<sub>2</sub> affinity.<sup>18</sup> Unmetallated *trans*-porphyrin bearing two 8-carboxylfunctionalized naphthalene spacers represented a unique example of a reversible, redox-controlled porphyrin-porphodimethane interconversion via a sequential intramolecular ring opening and closure reaction.<sup>19</sup> In comparison to the case of macrocycles, introduction of other heterocyclic systems into the 8-position of naphthoic acid has rarely been investigated.<sup>20</sup> Taking these facts into account, we conceived that molecules bearing both pyrazolo[3,4-b]pyridine and naphthoic acid units would be applicable as potential multifunctional materials. Nevertheless, the preparation of these compounds still remained unknown.

In recent years, much attention has been paid to the modification and synthesis of the pyrazolo[3,4-b]pyridine scaffold for drug discovery purposes.<sup>21</sup> The main strategies for the construction of pyrazolo[3,4-b]pyridines were focused on the three-component reaction of 5-aminopyrazoles, aldehydes and appropriate cyclic ketones by various methods.<sup>22</sup> Because 8-formyl-1-naphthoic acid is not readily available, functionalization at the 8-position of naphthoic acid is often accessed by using acenaphthenequinone as a precursor via multi-step transformation.<sup>23</sup> Recently, we found that three-component reaction of acenaphthylene-1,2-dione, 1Hpyrazol-5-amines and ketones could be performed facilely in acetic acid to provide the 8-carboxylnaphthyl-functionalized pyrazolo[3,4-b]pyridine derivatives. To the best of our knowledge, the reaction was the first synthesis of 8-heterocycle-functionalized naphthoic acid in a one-pot, cascade manner. Herein, we report these results.

Our studies commenced with the reaction of 3-(1-methyl-1Hindol-3-yl)-3-oxopropanenitrile (1b), acenaphthylene-1,2-dione (2) and 3-methyl-1-phenyl-1*H*-pyrazol-5-amine (3b) in HOAc medium at 120 °C. In our previous work, three-component reaction of 1b, 3b and isatin in HOAc/H<sub>2</sub>O solvent was found to produce spirooxindole derivatives.24 Similar results were observed as well by Shi et al. in the reaction of 2, 3b and 1,3-dicarbonyl compounds.<sup>25</sup> So, our initial attempt for the selected reaction was to generate spiro-compound 4' (Scheme 1). However, unexpectedly, a new product different from 4' was obtained. All the analytical data showed that the three reactants were all included in the formation of final product, producing a novel naphthoic acid functionalized with pyrazolo[3,4-b]pyridine, 4b (Scheme 1). The definite structure of 4b was further confirmed by X-ray single crystal analysis (Fig. 1).26 This surprising result is of value to us not only because we are interested in the design of the new threecomponent reaction<sup>27</sup> but also because we were unable to find examples of other methods allowing for such convenient synthesis of pyrazolo[3,4-b]pyridines simultaneously containing naphthoic acid and indole units in the related literature.

Encouraged by the result, we next made an effort to optimize the reaction conditions. It was found that in HOAc medium, lowering the reaction temperature led to inhibition of the reaction and thus a relatively poor yield of product (Table 1, entries 1–3). Other protic solvents such as EtOH,  $H_2O$  were examined as well under refluxing condition. However, no desired reaction was observed

Key Laboratory of Organic Synthesis of Jiangsu Province, College of Chemistry, Chemical Engineering and Materials Science, Soochow University, Suzhou215123, China. E-mail: xuxp@suda.edu.cn, chemjsj@suda.edu.cn; Fax: +86 512 6588 0307; Tel: +86 512 6588 0307

<sup>&</sup>lt;sup>†</sup> Electronic supplementary information (ESI) available: Experimental procedures, characterization data, <sup>1</sup>H and <sup>13</sup>C NMR spectra of compounds **4**. CCDC reference number 844424. For ESI and crystallographic data in CIF or other electronic format see DOI: 10.1039/c1ob06624b



Scheme 1 An unexpected formation of product 4b.



Fig. 1 X-Ray crystal structure of product 4b.

under the conditions (Table 1, entries 4–5). Then we turned our attention to the use of Brønsted acid catalysis. When 30 mol% *p*-toluenesulfonic acid was added to the reaction mixture in EtOH or H<sub>2</sub>O, respectively, no expected reaction occurred (Table 1, entries 6–7). Aprotic solvents including DMF and acetonitrile were also employed in the presence of 30 mol% *p*-toluenesulfonic acid, but the reactions were messy which resulted in complex mixtures which were impossible to separate into analytically pure products (Table 1, entries 1, entries 8–9).

Having established the optimal conditions (120 °C, HOAc), we subsequently investigated the substrate scope of the transformation. As shown in Table 2, substituents such as methyl, bromo, methoxycarbonyl, benzyl in the indole ring, and phenyl and methyl in the pyrazole ring, were well tolerated in the reactions, leading to the final products in satisfactory yields (up to 85%). To our surprise, when 3-methyl-1*H*-pyrazol-5-amine ( $\mathbb{R}^3 = \mathbb{H}$ ), one candidate in the compound **3** series, was introduced in the reaction, no positive outcome was returned. Under the standard

 Table 1
 Optimization of reaction conditions<sup>a</sup>

Entry	Solvent <sup>b</sup>	T∕°C	Time/h	Yield (%) <sup>c</sup>
1	АсОН	120	8	76
2	AcOH	100	20	54
3	AcOH	80	36	26
4	EtOH	80	48	0
5	$H_2O$	100	24	0
6 <sup><i>d</i></sup>	EtOH	80	48	0
$7^d$	$H_2O$	100	24	0
8 <sup>d</sup>	DMF	155	24	complex mixture
9 <sup>d</sup>	CH <sub>3</sub> CN	80	24	complex mixture

<sup>&</sup>lt;sup>*a*</sup> Molar ratio 1b:2:3b = 1:1:1. <sup>*b*</sup> 4 mL solvent was used. <sup>*c*</sup> Isolated yield. <sup>*d*</sup> These reactions were carried out in the presence of 30 mol% *p*-toluenesulfonic acid.

conditions, 3-methyl-1H-pyrazol-5-amine remained intact and only condensation between 1 and 2 occurred. We supposed that the lower electronic density of the pyrazole ring might result in its weak nucleophilicity. Thus, 3-methylisoxazol-5-amine was selected as an analog of 3 for further inspection; however, no promising result was obtained under optimal conditions.

On the basis of the experiments, a possible mechanism was proposed for the formation of 4 as shown in Scheme 2. First, condensation of 1 and 2 occurred to generate the intermediate A. Then, intermolecular Michael addition of 3 to A, followed by an intramolecular nucleophilic cyclization *via* B, led to the formation of C. After elimination of water, D was thus produced. In the presence of an oxidant such as oxygen, D was oxidized and converted to product 4.

After successful access to the indole containing pyrazolo[3,4b]pyridine-functionalized naphthoic acid, our curiosity was turned to seeking substitutes for 1 for wider generality of the reaction. It was fortunately found that a 1,3-dicarbonyl compound and its analog were also proven to be good candidates for this transformation. Two representative examples are listed in Scheme 3. The yields of desired products were higher than those with 1 as reactant.







Scheme 2 A possible mechanism for the formation of 4.

In conclusion, we have developed a novel and efficient approach to 8-carboxylnaphthyl-functionalized pyrazolo[3,4-b]pyridine derivatives *via* a one-pot, three-component condensation involving acenaphthylene-1,2-dione and 1*H*-pyrazol-5-amine in HOAc medium. It was the first direct conversion of

acenaphthenequinone to a naphthoic acid fragment *via* C–C bond cleavage without the need for multi-step transformation. An overall study concerning the impact of structural and functional motifs on the reaction is currently in progress in our laboratory.



Scheme 3 Synthesis of 4q and 4r using 1,3-dicarbonyl compounds as substrates.

## Acknowledgements

The work was partially supported by the National Natural Science Foundation of China (No. 21042007, 21172162), Nature Science Basic Research of Jiangsu Province for Higher Education (No. 10KJB150016), the Priority Academic Program Development of Jiangsu Higher Education Institutions and Key Project in Science and Technology Innovation Cultivation Program of Soochow University.

## Notes and References

- 1 G. L. Beutner, J. T. Kuethe, M. M. Kim and N. Yasuda, J. Org. Chem., 2009, 74, 789–794.
- 2 5-Aryl-pyrazolo[3,4-b]pyridines: (a) J. Witherington, V. Bordas, S. L. Garland, D. M. B. Hickey, R. J. Ife, J. Liddle, M. Saunders, D. G. Smith and R. W. Ward, *Bioorg. Med. Chem. Lett.*, 2003, **13**, 1577–1580; (b) 6-aryl-pyrazolo[3,4-b]pyridines: J. Witherington, V. Bordas, A. Gaiba, N. S. Garton, A. Naylor, A. D. Rawlings, B. P. Slingsby, D. G. Smith, A. K. Takle and R. W. Ward, *Bioorg. Med. Chem. Lett.*, 2003, **13**, 3055–3057. 6-Heteroaryl-pyrazolo[3,4-b]pyridines: (c) J. Witherington, V. Bordas, A. Gaiba, N. S. Garton, A. Naylor, A. D. Rawlings, B. P. Slingsby, D. G. Smith, A. K. Takle and R. W. Ward, *Bioorg. Med. Chem. Lett.*, 2003, **13**, 3055–3057. 13, 3059–3062.
- 3 B. Lynck, M. Khan, H. Teo and F. Pedrotti, *Can. J. Chem.*, 1988, **66**, 420–428.
- 4 Y. Fujikama, M. Suzuki, H. Iwasaki, M. Sakashita, M. Kitahara, EP 339358, 1989 [*Chem. Abstr.*, 1990, **113**, 23903].
- 5 F. Manetti, S. Schenone, F. Bondavalli, C. Brullo, O. Bruno, A. Ranise, L. Mosti, G. Menozzi, P. Fossa, M. L. Trincavelli, C. Martini, A. Martinelli, C. Tintori and M. Botta, *J. Med. Chem.*, 2005, 48, 7172– 7185.
- 6 J. N. Hamblin, T. D. R. Angell, S. P. Ballantine, C. M. Cook, A. W. J. Cooper, J. Dawson, C. J. Delves, P. S. Jones, M. Lindvall, F. S. Lucas, C. J. Mitchell, M. Y. Neu, L. E. Ranshaw, Y. E. Solanke, D. O. Somers and J. O. Wiseman, *Bioorg. Med. Chem. Lett.*, 2008, 18, 4237–4241.
- 7 L. Revesz, E. Blum, F. E. Di Padova, T. Buhl, R. Feifel, H. Gram, P. Hiestand, U. Manning, U. Neumann and G. Rucklin, *Bioorg. Med. Chem. Lett.*, 2006, 16, 262–266.
- 8 Y. L. Chen, WO9534563 A1, 1995.
- 9 (a) J. A. Lowe, US4891375, 1990; (b) S. P. Hollinshead, B. E. Huff, WO9904778, 1999; (c) S. F. Barnett, D. C. Heimbrook, WO9910523, 1999; (d) C. Z. Ding, R. S. Bhide, WO9918951, 1999.
- 10 G. D. Hartman, M. S. Egberston, W. Halczenko, W. L. Laswell, M. E. Duggan, R. L. Smith, A. M. Naylor, P. D. Manno, R. J. Lynch, G. Zhang, C. T. Chang and R. J. Gould, *J. Med. Chem.*, 1992, 35, 4640–4642.

- 11 J. Y. L. Chang, D. Zhao, D. L. Hughes and E. J. J. Grabowski, *Tetrahedron*, 1993, 49, 5767–5776.
- 12 I. Rivero-Cruz, L. Acevedo, J. A. Guerrero, S. Martinez, R. Bye, R. Pereda-Miranda, S. Franzblau, B. N. Timmermann and R. Mata, J. Pharm. Pharmacol., 2005, 5, 1117–1126.
- 13 J. Pandey, M. Mishira, S. S. Bisht, A. Sharma and R. P. Tripathi, *Tetrahedron Lett.*, 2008, 49, 695–698.
- 14 J. A. Aikins, M. Haurez, J. R. Rizzo, J. P. Van Hoeck, W. Brione, J. P. Kestemont, C. Stevens, X. Lemair, G. A. Stephenson, E. Marlot, M. Forst and I. N. Houpis, *J. Org. Chem.*, 2005, **70**, 4695–4705.
- 15 D. P. Rotella, Z. Sun, Y. Zhu, J. Krupinski, R. Pongrac, L. Seliger, D. Normandin and J. E. Macor, *J. Med. Chem.*, 2000, **43**, 5037– 5043.
- 16 G. Xu, T. L. Hartman, H. Wargo, J. A. Turpin, R. W. Buckheit and M. Cushman, *Bioorg. Med. Chem.*, 2002, 10, 283–290.
- 17 L. M. V. Tillekeratne, A. Sherette, P. Grossman, L. Hupe, D. Hupe and R. A. Hudson, *Bioorg. Med. Chem. Lett.*, 2001, **11**, 2763– 2767.
- 18 C. K. Chang and M. P. Kondylis, J. Chem. Soc., Chem. Commun., 1986, 316–318.
- 19 M. Harmjanz, H. S. Gill and M. J. Scott, J. Am. Chem. Soc., 2000, 122, 10476–10477.
- 20 (a) A. M. Kates, G. D. Tirzit and G. Y. Dubur, *Chem. Heterocycl. Compd.*, 1972, **8**, 188–189; (b) M. Matschke, R. Beckert, L. Kubicova and C. Biskup, *Synthesis*, 2008, 2957–2962.
- 21 For recent examples, see: (a) K. Bedjeguelal, R. Rabot, EI B. Kaloun, P. Mayer, A. Marchand, N. Rahier, P. Schambel, H. Bienayme, WO2011045344 A1, 2011; (b) H. A. Rajapakse, K. P. Moore, P. G. Nantermet, J. M. Sanders, S. Parmentier-Batteur, R. J. Mark, US20100113415 A1, 2010; (c) J. Dotson, T. Heffron, A. G. Olivero, D. P. Sutherlin, S. Staben, S. Wang, B.-Y. Zhu, I. S. Chuckowree, A. J. Folkes, N. C. Wan, WO2010059788 A1, 2010; (d) M. Tandon, S. M. Ali, M. Ashwell, J. Wang, N. Namdev, J. Hill, D. Neil, C. Brassard, A. Filikov, R. Palma, D. Vensel, WO2010078427 A1, 2010; (e) Z. Huang, Y. Hu, Y. Zhou and D. Shi, ACS Comb. Sci., 2011, 13, 45-49; (f) P. K. Sharma, K. Singh, S. Kumar, S. N. Dhawan, S. Lal, H. Ulbrich and G. Dannhardt, Med. Chem. Res., 2011, 20, 239-244; (g) B. Jiang, Y.-P. Liu and S.-J. Tu, Eur. J. Org. Chem., 2011, 3026-3035; (h) J. Quiroga, Y. Diaz, B. Insuasty, R. Abonia, M. Nogueras and J. Cobo, Tetrahedron Lett., 2010, 51, 2928-2930; (i) S. Lee and S. B. Park, Org. Lett., 2009, 11, 5214–5217; (j) X. Zhang, X. Li, X. Fan, X. Wang, J. Wang and G. Ou, Aust. J. Chem., 2009, 62, 382–388; (k) Y.-L. Zhong, M. G. Lindale and N. Yasuda, Tetrahedron Lett., 2009, 50, 2293-2297; (1) T. E. Ali, Eur. J. Med. Chem., 2009, 44, 4385-4392.
- (a) J. Quiroga, D. Mejia, B. Insuasty, R. Abonia, M. Nogueras, A. Sanchez, J. Cobo and J. N. Low, *Tetrahedron*, 2001, 57, 6947–6953;
  (b) J. Quiroga, A. Hormaza, B. Insuasty, C. Saitz and C. Jullian, J. *Heterocycl. Chem.*, 1998, 35, 575–578; (c) I. Drizin, R. J. Altenbach, S. A. Buckner, K. L. Whiteaker, V. E. Scott, J. F. Darbyshire, V. Jayanti, R. F. Henry, M. J. Coghlan, M. Gopalakrishnan and W. A. Carroll, *Bioorg. Med. Chem.*, 2004, 12, 1895–1904; (d) J. Quiroga, J. Portilla, H. Serrano, R. Abonia, B. Insuasty, M. Nogueras and J. Cobo, *Tetrahedron Lett.*, 2007, 48, 1987–1990; (e) B. Jiang, X. Wang, F. Shi, S. J. Tu and G. G. Li, *Org. Biomol. Chem.*, 2011, 9, 4025–4028; (f) B. Jiang, G. Zhang, N. Ma, F. Shi, S. J. Tu, P. Kaur and G. G. Li, *Org. Biomol. Chem.*, 2011, 9, 3834–3838.
- (a) M. Harmjanz and M. J. Scott, *Inorg. Chem.*, 2000, **39**, 5428–5429;
   (b) M. Harmjanz, H. S. Gill and M. J. Scott, *J. Org. Chem.*, 2001, **66**, 5347–5383;
   (c) M. Harmjanz and M. J. Scott, *Chem. Commun.*, 2000, 397–398.
- 24 T. Chen, X.-P. Xu and S.-J. Ji, J. Comb. Chem., 2010, 12, 659-663.
- 25 H. Chen and D. Q. Shi, J. Comb. Chem., 2010, 12, 571-576.
- 26 Crystallographic data for the structure of 4b·DMF reported in this paper have been deposited at the Cambridge Crystallographic Data Centre with No. CCDC 844424. Structural parameters for 4b·DMF: data collection: Rigaku Mercury CCD area detector; crystal size: 0.60 × 0.50 × 0.20 mm<sup>3</sup>; C<sub>37</sub>H<sub>30</sub>N<sub>6</sub>O<sub>3</sub>, M<sub>r</sub> = 606.67, monoclinic, space group *P*21/*c*, *a* = 11.3442(11), *b* = 19.9830(18), *c* = 13.8952(13) Å, *α* = 90.00, β = 99.660(3), γ = 90.00°, V = 3105.3(5) Å<sup>3</sup>, Z = 4, D<sub>c</sub> = 1.298 g cm<sup>-3</sup>, R<sub>[l > 2σ(l)]</sub> = 0.0789, wR<sub>[l > 2σ(l)]</sub> = 0.1621.
  27 (*a*) Z.-L. Shen, S.-J. Ji, S.-Y. Wang and X.-F. Zeng, *Tetrahedron*, 2005,
- 27 (a) Z.-L. Shen, S.-J. Ji, S.-Y. Wang and X.-F. Zeng, *Tetrahedron*, 2005, 61, 10552–10558; (b) C. Sun, S.-J. Ji and Y. Liu, *Tetrahedron Lett.*, 2007, 48, 8987–8989; (c) S.-L. Zhu, S.-J. Ji and Y. Zhang, *Tetrahedron*, 2007, 63, 9365–9372; (d) S.-L. Zhu, S.-J. Ji, X.-M. Su and Y. Liu, *Tetrahedron*

Lett., 2008, **49**, 1777–1781; (e) S.-L. Zhu, S.-J. Ji and Y. Liu, *Tetrahedron Lett.*, 2008, **49**, 2578–2582; (f) X.-J. Wu, R. Jiang, B. Wu, X.-M. Su, X.-P. Xu and S.-J. Ji, *Adv. Synth. Catal.*, 2009, **351**, 3150–3156; (g) K. Zhao, X.-P. Xu, S.-L. Zhu, D.-Q. Shi, Y. Zhang and S.-J. Ji, *Synthesis*, 2009, 2697–2708; (h) X.-J. Wu, X.-P. Xu, X.-M. Su, G. Chen, Y. Zhang and S.-J. Ji, *Eur. J. Org. Chem.*, 2009, 4963–4970; (i) Z.-L. Shen, X.-P. Xu and S.-J. Ji, *J. Org. Chem.*, 2010, **75**, 1162–1167; (j) X. Zhu, X.-P.

Xu, C. Sun, H.-Y. Wang, K. Zhao and S.-J. Ji, *J. Comb. Chem.*, 2010, **12**, 822–828; (*k*) K. Zhao, S.-L. Zhu, D.-Q. Shi, Y. Zhang, X.-P. Xu and S.-J. Ji, *Synthesis*, 2010, 1793–1803; (*l*) X.-J. Wu, R. Jiang, X.-P. Xu, X.-M. Su, W.-H. Lu and S.-J. Ji, *J. Comb. Chem.*, 2010, **12**, 829–835; (*m*) X. Zhu, X.-P. Xu, C. Sun, T. Chen, Z.-L. Shen and S.-J. Ji, *Tetrahedron*, 2011, **67**, 6375–6387; (*n*) T. Chen, X.-P. Xu, H.-F. Liu and S.-J. Ji, *Tetrahedron*, 2011, **67**, 5469–5476.